Gene · 8739
NIH grants1,203
NIH grants whose papers are about the gene, through NIH's grant-paper links.
221 to 240 of 1,203
Download this page as JSON| Grant | Title | HRK papers | Newest fiscal year |
|---|---|---|---|
| T32CA140044 | Proteogenomics of Cancer Training Program | 2 | 2024 |
| I01BX004423 | Target, Function and Mechanism of LLS30 in Castration Resistant Prostate Cancer | 1 | 2024 |
| IK2CX002336 | Genetic architecture of substance use disorders and major depression | 1 | 2024 |
| K01AA028292 | Characterizing the phenotypic spectrum associated with genetic liability for alcohol use disorder | 1 | 2024 |
| K08CA245209 | Enhancing Venetoclax Activity in Chemoresistant Acute Myeloid Leukemia | 1 | 2024 |
| K23HL150237 | Identifying predictors of treatment response in systemic sclerosis-related interstitial lung disease | 1 | 2024 |
| P01AG049665 | Disordered Proteostasis as a Driver of Disease in the Aging Lung | 1 | 2024 |
| P01CA084203 | Photodynamic Priming of Cancer and Image-guidance for Optimal Immune Response | 1 | 2024 |
| P01CA093900 | The Biology of Prostate Cancer Skeletal Metastases | 1 | 2024 |
| P01CA171983 | Targeted Sphingolipid Metabolism for Treatment of AML | 1 | 2024 |
| P01CA236749 | Understanding and Overcoming T cell Immunosuppression in Glioblastoma | 1 | 2024 |
| P42ES017198 | Puerto Rico Testsite for Exploring Contamination Threats (PROTECT) | 1 | 2024 |
| P50CA070907 | Targeting Lung Cancer Vulnerabilities | 1 | 2024 |
| R01AG015819 | Risk Factors, Pathology, and Clinical Expressions of AD | 1 | 2024 |
| R01AI151707 | Heterogeneity of T cell phenotype and function in food allergy | 1 | 2024 |
| R01CA150925 | Autophagy regulation of apoptosis and necroptosis within cell populations | 1 | 2024 |
| R01CA168517 | Mcl-1/Bfl-1 in apoptosis and signal transduction: a structure/function approach | 1 | 2024 |
| R01CA190394 | Targeting the cytokine circuitry of KRAS-driven lung cancer | 1 | 2024 |
| R01CA225996 | BAK Autoactivation in Hematological Malignancies | 1 | 2024 |
| R01CA235622 | Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen | 1 | 2024 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8739/grants?page=12